Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma

International Journal of Cancer

Volumn 129, Issue 9, 2011, Pages 2093-2103

  Doucette, Tiffany ^a   Yang, Yuhui ^a   Zhang, Wei ^a   Fuller, Gregory N ^a   Suki, Dima ^a   Fults, Daniel W ^b   Rao, Ganesh ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; Bcl 2; glioma; necrosis; oligodendroglioma

Indexed keywords

CASPASE 3; HISTONE H3; PLATELET DERIVED GROWTH FACTOR B;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTO ONCOGENE; SURVIVAL TIME; TUMOR CELL;

ANIMALS; CELL LINE; CELL PROLIFERATION; CHICKENS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM GRADING; OLIGODENDROGLIOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-SIS;

EID: 80052270052     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25869     Document Type: Article

References (50)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P,. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. (Pubitemid 47103521)
2. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC,. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 2006; 24: 1246-52. (Pubitemid 46622027)
3. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W,. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24: 2707-14. (Pubitemid 46630566)
4. Evan GI, Vousden KH,. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-8. (Pubitemid 32467043)
5. Yip KW, Reed JC,. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-406.
6. Shih AH, Holland EC,. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2006; 232: 139-47. (Pubitemid 43170963)
7. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-710. (Pubitemid 350070717)
8. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E,. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009; 4: e7752.
9. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC,. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004; 64: 4783-9. (Pubitemid 38924521)
10. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC,. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001; 15: 1913-25. (Pubitemid 32738621)
11. Appolloni I, Calzolari F, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P,. PDGF-B induces a homogeneous class of oligodendrogliomas from embryonic neural progenitors. Int J Cancer 2009; 124: 2251-9.
12. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W,. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 2007; 104: 11736-41. (Pubitemid 47175082)
13. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H,. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007; 282: 18634-44. (Pubitemid 47100243)
14. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC,. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009; 23: 1327-37.
15. Tchougounova E, Kastemar M, Brasater D, Holland EC, Westermark B, Uhrbom L,. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 2007; 26: 6289-96. (Pubitemid 47462106)
16. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
17. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y,. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6-8. (Pubitemid 24042076)
18. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S,. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997; 90: 1168-74. (Pubitemid 27314153)
19. Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR,. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 2004; 26: 870-7. (Pubitemid 39299306)
20. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R,. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 1999; 67: 763-8.
21. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC,. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-14. (Pubitemid 27106152)
22. Stegh AH, Chin L, Louis DN, DePinho RA,. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 2008; 7: 2833-9.
23. McDonald FE, Ironside JW, Gregor A, Wyatt B, Stewart M, Rye R, Adams J, Potts HW,. The prognostic influence of bcl-2 in malignant glioma. Br J Cancer 2002; 86: 1899-904.
24. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN,. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000; 25: 55-7. (Pubitemid 30257036)
25. Holland EC, Li Y, Celestino J, Dai C, Schaefer L, Sawaya RA, Fuller GN,. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol 2000; 157: 1031-7. (Pubitemid 32109394)
26. Rao G, Pedone CA, Coffin CM, Holland EC, Fults DW,. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia 2003; 5: 198-204. (Pubitemid 36754051)
27. Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M,. BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett 1998; 440: 419-24. (Pubitemid 29052326)
28. McCall TD, Pedone CA, Fults DW,. Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice. Cancer Res 2007; 67: 5179-85. (Pubitemid 46997255)
29. Holland EC, Varmus HE,. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 1998; 95: 1218-23. (Pubitemid 28124939)
30. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K,. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 2006; 30: 657-64. (Pubitemid 44265019)
31. Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou YH, Liao WS, Fuller GN, Zhang W,. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003; 63: 4315-21. (Pubitemid 36950996)
32. Green DR, Evan GI,. A matter of life and death. Cancer Cell 2002; 1: 19-30. (Pubitemid 41039172)
33. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R,. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci 1998; 155: 68-75. (Pubitemid 28141061)
34. Deininger MH, Weller M, Streffer J, Meyermann R,. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma. Cancer 1999; 86: 1832-9. (Pubitemid 29513054)
35. Hara A, Hirose Y, Yoshimi N, Tanaka T, Mori H,. Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors. Neurol Res 1997; 19: 623-8. (Pubitemid 28006646)
36. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A,. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95: 2633-43.
37. Reed JC,. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008; 111: 3322-30.
38. Adams JM, Cory S,. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6. (Pubitemid 28406819)
39. Arai M, Sasaki A, Saito N, Nakazato Y,. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int 2005; 55: 122-9. (Pubitemid 40477223)
40. Wick W, Wild-Bode C, Frank B, Weller M,. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. J Neurochem 2004; 91: 1275-83. (Pubitemid 39658554)
41. Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA,. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 2008; 105: 10703-8.
42. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, DePinho RA, Chin L,. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007; 21: 98-111. (Pubitemid 46089711)
43. Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006; 116: 261-70. (Pubitemid 43121811)
44. Barker FG, II, Davis RL, Chang SM, Prados MD,. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 1996; 77: 1161-6. (Pubitemid 26080909)
45. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R,. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002; 51: 2-12;discussion 3.
46. Krakstad C, Chekenya M,. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010; 9: 135.
47. Jiang Z, Zheng X, Rich KM,. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 2003; 84: 273-81. (Pubitemid 36182269)
48. Julien T, Frankel B, Longo S, Kyle M, Gibson S, Shillitoe E, Ryken T,. Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol 2000; 53: 360-8; discussion 8-9.
49. Hetschko H, Voss V, Horn S, Seifert V, Prehn JH, Kogel D,. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 2008; 86: 265-72.
50. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W,. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27: 6646-56.